Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893844 | 0.95 | APLNR (0.49) | APLNRTSHRGAAMEN1KMT2A | |
| SCHEMBL14258516 | 0.89 | APLNR (0.53) | APLNRGAAMEN1KMT2ATDP1 | |
| SCHEMBL31143867 | 0.84 | TSHR (0.52) | APLNRTSHRGAAMEN1KMT2A | |
| SCHEMBL6293458 | 0.83 | APLNR (0.42) | APLNRGAAMEN1KMT2ATDP1 | |
| SCHEMBL27732646 | 0.82 | APLNR (0.54) | APLNRGAAMEN1KMT2AKDM4E | |
| SCHEMBL29139522 | 0.82 | APLNR (0.50) | APLNRGAAMEN1KMT2ATDP1 | |
| SCHEMBL23419356 | 0.81 | APLNR (0.49) | APLNRTSHRMEN1KMT2ATDP1 | |
| SCHEMBL5832179 | 0.81 | APLNR (0.49) | APLNRTSHRGAAMEN1KMT2A | |
| SCHEMBL10535135 | 0.81 | APLNR (0.53) | APLNRGAAMEN1KMT2ATDP1 | |
| SCHEMBL3458796 | 0.79 | APLNR (0.54) | APLNRGAAMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2019202049-A1 | CELL PENETRATING PEPTIDES | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556767-A1 | CELL PENETRATING PEPTIDES | Universidade De Santiago De Compostela (ES) | 2019-10-23 | — | — | EP | disclosed |
| US-10344261-B2 | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-07-09 | — | — | US | disclosed |
| US-10344261-B2 | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-07-09 | — | — | US | disclosed |
| CN-104661683-A | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS PTY LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | disclosed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | disclosed |
| EP-2776070-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharmaceuticals Ltd (AU) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013067597-A1 | IMMUNOMODULATORY CONJUGATES | ASCEND BIOPHARMACEUTICALS PTY LTD (AU) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | CLEC4M, TLR3, CD74 | APLNR 1177/4885TSHR 4346/4885GAA 414/4885 |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | CLEC4M, TLR3, CD74 | APLNR 1177/4885TSHR 4346/4885GAA 414/4885 |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | APLNR 524/4885TSHR 4599/4885GAA 324/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | APLNR 2605/4885TSHR 1768/4885GAA 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.